Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.

In the previous phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune therapy. The current study builds on this work, and will explore different 4-dose treatment regimens, which are designed to enhance the patients' response and determine the best therapeutic approach. During the study, patients will receive a controlled dose of cat allergen in an environmental exposure chamber both before and after treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the different treatment regimes. The double-blind, randomized, placebo-controlled trial will include a total of 120 volunteers with confirmed cat allergies. The study, which is already underway in Canada, is progressing well with approximately 20% of patients enrolled for screening so far.

"This study is of great importance for Circassia as it is designed to define the most effective treatment regime for our ToleroMune allergy products, and in particular for the phase III studies of our cat-allergy therapy that are planned to begin in the second half of 2009," said Steve Harris, Circassia's CEO. "The results of our trials to date show that our ToleroMune approach offers patients substantial potential benefits. Conventional allergy treatments either address symptoms only or require many doses over a period of months under specialist supervision because they can result in serio
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
(Date:10/22/2014)... LOUIS , Oct. 21, 2014  Early ... often subtle or unnoticed, but new technology, coupled ... outcomes and leading to earlier detection of eye ... affects 29 million Americans. If left untreated, these ... even blindness. Recently, optometric researchers ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... drinking among young adult men may lead to increased blood ... didn,t cause a similar rise in blood pressure for young ... fact, when young adult women drank lightly or moderately, their ... study found. "This finding parallels studies in older adult ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... Union asks board member to seek restatement of Beth ... Staples director Martin Trust,should apply the same Sarbanes-Oxley standards ... role on the board of Beth Israel Deaconess,Medical Center ... East. Trust is the CEO of Samtex and a ...
... Advisory Board Company,(Nasdaq: ABCO ) announced today ... Michael T. Kirshbaum, Chief Financial Officer and Robert,Musslewhite, ... upcoming investor conferences., Mr. Williams will present ... at,the UBS 18th Annual Global Healthcare Services Conference, ...
... in Long-Term Care: A Board of Directors Dashboard, ... Office of Inspector General (OIG) for the Department of ... Association (HCCA),present the challenges and opportunities for the boards ... of Care Dashboard." A,Quality of Care Dashboard is a ...
... Fla., Feb. 6 Mangrove Employer Services, a,leading ... Payroll, Benefits Administration and Self Service solutions,announces the ... Mangrove Employer Services teamed up with an ... in electronic benefits,payment services, in 2007 to provide ...
... NAPA, Calif., Feb. 6 Senetek PLC (OTC,Bulletin ... the development,of technologies that target the science of ... on Pyratine-6(TM) at the 66th Annual Meeting,of the ... In his presentation to the Academy, Dr. ...
... after , , WEDNESDAY, Feb. 6 (HealthDay News) -- An advanced ... harbingers of Alzheimer,s disease, can develop in just 24 hours. ... Hyman, leader of the group reporting the finding in the ... develop, damage is evident in nearby nerve cells almost immediately, ...
Cached Medicine News:Health News:Staples Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Advisory Board Company to Present at Upcoming Conferences 2Health News:OIG and HCCA Issue Government-Industry Roundtable Report 2Health News:Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches 2Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Alzheimer's Plaques Can Form in One Day 2
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
0-3.5 LPM Oxygen Flowmeter with Chemetronmale inlet...
0-15 LPM Oxygen Flowmeter with Chemetron male inlet...
(1/4-15 LPM). 50 psi back inlet, wall mounted, 1/8" NPT female....
Medicine Products: